Toripalimab-tpzi: the monoclonalantibodies approved by fda this year 

Share This Post

Toripalimab-tpzi is another of the #monoclonalantibodies approved by #fda this year, to treat recurrent or #metastatic nasopharyngeal #carcinoma when used together with or following other therapies*

It is expressed in a recombinant Chinese Hamster Ovary (#CHO) mammalian cell expression system, reminding again, if still needed, the importance of CHO cells in producing the #drugs of today and tomorrow and demonstrating the intense activity of research and development in this field.

We at Magellan Biologics & Consulting proudly support the scientific community at early stage in the discovery of new candidates with #CHO4Tx® our transient protein expression system in CHO cells.

*FDA novel Drug Approvals for 2023

Get updates

Subscribe To Our Newsletter

More To Explore

Interested in our products?

Drop us a line and keep in touch

Your cart is currently empty.

Welcome on board!

Subrscribe to our Newsletter
and stay updated!

Get Updates!

If you opt in above we use this information send related content